Elsevier

Vaccine

Volume 32, Issue 48, 12 November 2014, Pages 6377-6389
Vaccine

Review
Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer

https://doi.org/10.1016/j.vaccine.2014.06.065Get rights and content

Abstract

Synthetic oligonucleotides (ODN) that express unmethylated “CpG motifs” trigger cells that express Toll-like receptor 9. In humans this includes plasmacytoid dendritic cells and B cells. CpG ODN induce an innate immune response characterized by the production of Th1 and pro-inflammatory cytokines. Their utility as vaccine adjuvants was evaluated in a number of clinical trials. Results indicate that CpG ODN improve antigen presentation and the generation of vaccine-specific cellular and humoral responses. This work provides an up-to-date overview of the utility of CpG ODN as adjuvants for vaccines targeting infectious agents and cancer.

Introduction

Vaccines are highly effective public health interventions, having saved millions of lives by preventing infectious diseases. The efficacy of a vaccine is determined by the magnitude, duration and quality of the immune response it induces. Depending upon the disease, both the innate and adaptive arms of the immune system may contribute to protection. The innate immune response involves the activation of multiple cell types, including dendritic cells, macrophages, monocytes, neutrophils, basophils, eosinophils, lymphocytes and/or NK cells. The innate immune system provides a rapid response to pathogens, initiates pathogen clearance, and helps in the healing of damaged tissue. Cells of the adaptive immune system include primarily B and T lymphocytes. Adaptive immune responses develop more slowly but are highly specific and therefore critical for providing sterilizing immunity and long-term memory.

Successful vaccination requires a complex series of immune interactions. Professional APCs (dendritic cells and macrophages) as well as certain other immune cells (e.g. B lymphocytes) take up the vaccine Ag. The Ag is then digested and fragments presented to T lymphocytes via cell–cell interactions that require additional surface receptors. Ag-activated CD4 T cells provide help to Ag-specific B cells, supporting their proliferation, switch recombination and somatic hypermutation, resulting in the production of high-affinity Ab (an outcome measured in many clinical trials) [1], [2], [3]. CD8 T cells are also stimulated to proliferate and mature into cytotoxic effectors. These are typically measured by their production of Th1 cytokines, such as IFN-γ. Over the course of the vaccine-elicited response, Ag-specific memory B and T lymphocytes arise that persist long-term and provide protection from subsequent challenge [4], [5], [6], [7].

Toll-like receptors (TLR) belong to the family of pathogen recognition receptors that are triggered by pathogen-associated molecular patterns expressed by bacteria, viruses, fungi and protozoa. The basic structure of these receptors include an extracellular leucine-rich repeat region, a transmembrane domain and a cytosolic Toll/Interleukin-1 receptor domain. TLR stimulation contributes to the induction and maintenance of innate and adaptive immune pathways as well as memory function [3]. Eleven human and 13 mouse TLRs have been identified. These TLRs have been categorized based on their ligand specificity, signal transduction pathways, cellular expression profiles and subcellular localization. While human TLRs 1, 2, 4, 5 and 6 are localized on the cell membrane, TLRs 3, 7, 8, 9 and 10 are embedded in intracellular vesicles [8], [9], although TLR9 was found on the cellular membrane of human CD19+ B cells [10].

TLRs are expressed primarily on immune cells although other cells are known to contribute to host protection, such as barrier epithelial cells, can also express these receptors. Once triggered by pathogen, these cells produce pro-inflammatory cytokines and chemokines that support the recruitment of additional inflammatory mediators, type I interferon and antimicrobial peptides [11]. TLRs are also expressed on malignant cells and may play a role in oncogenesis and tumor progression by influencing the tumor microenvironment [9], [12], [13], [14].

Section snippets

Toll-like receptor 9

TLR9 recognizes the unmethylated CpG motifs present at high frequency in bacterial but rare in mammalian DNA. The TLR9 receptor is localized to in the endoplasmatic reticulum, late endosomal and lysosomal compartments of the intracellular milieu. Thus, internalization of pathogen-derived DNA is required for TLR9 triggering, an outcome that results from either intracellular infection or uptake of bacterial/viral particles by immune cells [15]. Once stimulated, TLR9 initiates a response biased

TLR9-mediated signaling cascade

The binding of CpG DNA to TLR9 induces proteolytic cleavage of the receptor [28], [29]. After exiting the ER, the TLR9 ectodomain is cleaved by asparagine endopeptidase and/or cathepsins [30], [31]. This truncated (rather than full length) form of TLR9 recruits myeloid differentiation factor 88 (MyD88) such that if proteolysis of the receptor is prevented, it becomes non-functional. The requirement for ectodomain cleavage provides an ancillary mechanism to restrict receptor activation to

CpG ODN

Bacterial DNA is the native ligand for TLR9 and synthetic oligonucleotides (ODN) that mimic the structure of bacterial DNA duplicate this activity. In humans, four distinct classes of CpG ODN have been identified based on differences in structure and the nature of the immune response they induce. Although each class contains at least one motif composed of a central unmethylated CG dinucleotide plus flanking regions, they differ in structure and immunological activity.

K-type ODNs (also referred

Anthrax

Anthrax is caused by the toxin-producing gram positive bacterium Bacillus Anthracis. The spores of this pathogen are highly resistant to environmental degradation (desiccation, heat, UV light) and many disinfectant solutions [49]. Protection against anthrax is provided by Abs targeting the ‘protective antigen’ (PA) component of the toxin.

The currently licensed human vaccine, Anthrax Vaccine Adsorbed (AVA) is administered as 6 subcutaneous (SC) injections over 18 months followed by annual

CpG ODN as an adjuvant in HIV-infected individuals

Chronic HIV infection is characterized by latent infection and impairment of CD4 T cells and the cytolytic activity of CD8 T cells. This contributes to a diminution in the immunogenicity of standard vaccines, placing HIV patients at higher risk for associated infections and increased mortality [83], [84]. CpG ODN were found to boost immunity in mice with depressed immune systems. However their utility in HIV-infected patients was uncertain, since they could potentially increase virus

Use of CpG ODN as stand-alone anti-tumor agents

CpG ODN were evaluated as stand alone anti-tumor agents in several clinical trials. While distinct from their use as vaccine adjuvants, results from those trials are described below as they provide insights into the immunostimulatory activity of CpG ODN. Based on the observation that CpG ODN can stimulate an innate immune response capable of decreasing tumor burden in animal models, CpG 7909 alone at doses up to 0.08 mg/kg SQ and 0.32 mg/kg IV was tested in humans. Evidence of in vivo activity

Conclusion and perspectives

This review focuses on the outcome of clinical trials in which CpG ODN were combined with vaccines targeting infectious diseases and cancer. Overall findings indicate that CpG ODN improve humoral and cellular immune responses when vaccines are administered to healthy individuals. CpG ODN accelerated the induction of protective Abs and supported the generation of higher and more persistent Ab titers with protein vaccines. This was best demonstrated by the extensive trials involving vaccines

Conflict of interest

Dr. Klinman and members of his lab have patents related to the use of CpG ODN. All rights to such patents have been assigned to the Federal Government.

References (143)

  • D.M. Klinman et al.

    Systemic but not mucosal immunity induced by AVA prevents inhalational anthrax

    Microbes Infect

    (2007)
  • S. Kamal et al.

    Anthrax: an update

    Asian Pac J Trop Biomed

    (2011)
  • M. Gu et al.

    Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109

    Vaccine

    (2007)
  • D. Rynkiewicz et al.

    Marked enhancement of the immune response to BioThrax(R) (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers

    Vaccine

    (2011)
  • R.J. Hopkins et al.

    Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers

    Vaccine

    (2013)
  • S. Wang et al.

    CpG oligodeoxynucleotide-adjuvanted fusion peptide derived from HBcAg epitope and HIV-Tat may elicit favorable immune response in PBMCs from patients with chronic HBV infection in the immunotolerant phase

    Int Immunopharmacol

    (2011)
  • H.L. Davis et al.

    CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans

    Vaccine

    (2000)
  • D.C. Freed et al.

    Evaluating functional antibodies in rhesus monkeys immunized with hepatitis B virus surface antigen vaccine with novel adjuvant formulations

    Vaccine

    (2011)
  • S.A. Halperin et al.

    A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant

    Vaccine

    (2003)
  • S.A. Halperin et al.

    Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults

    Vaccine

    (2006)
  • S.A. Halperin et al.

    Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age

    Vaccine

    (2012)
  • B.P. Sablan et al.

    Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine

    Vaccine

    (2012)
  • I. Sanz et al.

    Phenotypic and functional heterogeneity of human memory B cells

    Semin Immunol

    (2008)
  • I. Sagara et al.

    A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults

    Vaccine

    (2009)
  • Z. Moldoveanu et al.

    CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus

    Vaccine

    (1998)
  • C.L. Cooper et al.

    Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine

    Vaccine

    (2004)
  • C. Scheller et al.

    CpG oligodeoxynucleotides activate HIV replication in latently infected human T cells

    J Biol Chem

    (2004)
  • U. Klein et al.

    Germinal centres: role in B-cell physiology and malignancy

    Nat Rev Immunol

    (2008)
  • J.C. Weill et al.

    Human marginal zone B cells

    Annu Rev Immunol

    (2009)
  • I.A. Cockburn et al.

    Prolonged antigen presentation is required for optimal CD8+ T cell responses against malaria liver stage parasites

    PLoS Pathog

    (2010)
  • M. Guimond et al.

    Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells

    Nat Immunol

    (2009)
  • V. Vezys et al.

    Memory CD8 T-cell compartment grows in size with immunological experience

    Nature

    (2009)
  • J.C. Roach et al.

    The evolution of vertebrate Toll-like receptors

    Proc Natl Acad Sci USA

    (2005)
  • E. Vacchelli et al.

    Trial Watch: toll-like receptor agonists for cancer therapy

    Oncoimmunology

    (2013)
  • A. Eaton-Bassiri et al.

    Toll-like receptor 9 can be expressed at the cell surface of distinct populations of tonsils and human peripheral blood mononuclear cells

    Infect Immun

    (2004)
  • J. Tuomela et al.

    Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer

    Breast Cancer Res Treat

    (2012)
  • J. Hagstrom et al.

    TLR-4 expression and decrease in chronic inflammation: indicators of aggressive follicular thyroid carcinoma

    J Clin Pathol

    (2012)
  • S. Rakoff-Nahoum et al.

    Toll-like receptors and cancer

    Nat Rev Cancer

    (2009)
  • E. Latz et al.

    TLR9 signals after translocating from the ER to CpG DNA in the lysosome

    Nat Immunol

    (2004)
  • A.M. Krieg

    Therapeutic potential of Toll-like receptor 9 activation

    Nat Rev Drug Discov

    (2006)
  • H. Hemmi et al.

    A Toll-like receptor recognizes bacterial DNA

    NAT

    (2000)
  • V. Hornung et al.

    Quantitative expression of toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides

    J Immunol

    (2002)
  • Y. Suzuki et al.

    Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity

    Cancer Res

    (2004)
  • N. Kadowaki et al.

    Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens

    J Exp Med

    (2001)
  • E.P. Browne

    Regulation of B-cell responses by Toll-like receptors

    Immunology

    (2012)
  • J. Dement-Brown et al.

    Fc receptor-like 5 promotes B cell proliferation and drives the development of cells displaying switched isotypes

    J Leukoc Biol

    (2012)
  • H. Kumar et al.

    Pathogen recognition by the innate immune system

    Int Rev Immunol

    (2011)
  • S.E. Ewald et al.

    The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor

    Nature

    (2008)
  • B. Park et al.

    Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9

    Nat Immunol

    (2008)
  • S.E. Ewald et al.

    Nucleic acid recognition by Toll-like receptors is coupled to stepwise processing by cathepsins and asparagine endopeptidase

    J Exp Med

    (2011)
  • Cited by (263)

    • Mechanisms of type I interferon production by chicken TLR21

      2024, Developmental and Comparative Immunology
    View all citing articles on Scopus
    View full text